EUVIMEDEUVIMED entdecken
Open Access

Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice

Xiaofei Yin, Caroline Bickerton, Bryan MacDonald iD, Alessandro Arduini, Yunlong Shi, Mary Haas, Amy Deik, Mark Chaffin, Erika Kovacs-Bogdan, Julian Avila Pacheco, Maiwen Amegadjie, Bidur Bhandary und 10 weitere

Liver International · 2026

DOI: 10.1111/liv.70507 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2026. Verfasst von Xiaofei Yin und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association, American Heart Association-American Stroke Association, Bayer AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) spans from simple steatosis to metabolic dysfunction‐associated steatohepatitis (MASH) and can progress to cirrhosis or hepatocellular carcinoma. Despite its prevalence, effective therapies are lacking. Recent genome‐wide association studies identified a common missense variant (rs2642438) in the Mitochondrial Amidoxime Reducing Component 1 ( MTARC1 ) gene that protects against liver cirrhosis without increasing cardiovascular disease risk. Biochemical and disease risk signatures associated with carriers of this missense variant also aligned with those of a known loss‐of‐function MTARC1 variant, suggesting mARC1 inhibition as a potential MASLD treatment.

Methods

To validate mARC1 loss‐of‐function as protective against MASLD, we generated Mtarc1 knockout (KO) mice and placed them on a choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD). Effects of Mtarc1 KO on obesity and type 2 diabetes were explored using a high‐fat diet. Hepatocytes from Mtarc1 KO mice were isolated to explore the molecular mechanisms by which Mtarc1 KO impacts lipid metabolism.

Results

Mtarc1 KO mice exhibited no vital growth or development defects. With a high‐fat diet‐induced obesity model, obese Mtarc1 KO mice exhibited reduced liver mass and lower cholesterol levels, with no effect on glucose homeostasis. In a CDAHFD‐induced MASLD model, mARC1 deficiency significantly reduced liver steatosis, profibrosis, and inflammation. Untargeted metabolomics profiling further showed hepatic enrichment of phospholipids in Mtarc1 KO mice. Primary hepatocytes isolated from Mtarc1 KO mice exhibited reduced lipid droplet accumulation, decreased fatty acid uptake, and increased lipid secretion.

Conclusions

These findings support mARC1 inhibition as a promising therapeutic strategy for MASLD/MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverNon-alcoholic Fatty Liver DiseaseAnimalsMice, KnockoutMiceDiet, High-FatHepatocytesDisease Models, AnimalMaleMice, Inbred C57BLLiverLipid MetabolismCholine DeficiencyObesityAmidohydrolasesGPI-Linked Proteins

Stichwörter der Autor:innen

Mtarc1metabolic dysfunction‐associated steatotic liver diseasephospholipidprofibrosissteatosis

Substanzen

pantetheinaseAmidohydrolasesGPI-Linked Proteins

Autor:innen und Institutionen

  • Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Bayer U.S. LLC, Cambridge, Massachusetts, USA.
  • Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Bayer AG, Pharmaceutical Division, Berlin, Germany.
  • GI Division, Department of Medicine, Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Bryan MacDonald, Alison Leed

Förderung

  • American Heart Association
  • American Heart Association-American Stroke Association
  • Bayer AG
  • NHLBI NIH HHS
  • European Union
  • National Institutes of Health
  • European Commission
  • Bayer

Zitieren

APA

Yin, X., Bickerton, C., MacDonald, B., Arduini, A., Shi, Y., Haas, M., Deik, A., Chaffin, M., Kovacs-Bogdan, E., Pacheco, J. A., Amegadjie, M., Bhandary, B., Sadre, S., Rathjen, T., Papangeli, I., Chung, R. T., Goodman, R., Claussnitzer, M., Clish, C., …, & Ellinor, P. T. (2026). Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice. Liver International. https://doi.org/10.1111/liv.70507

Vancouver

Yin X, Bickerton C, MacDonald B, Arduini A, Shi Y, Haas M, et al. Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice. Liver International. 2026. doi:10.1111/liv.70507

BibTeX
@article{Yin2026,
  author = {Yin, Xiaofei and Bickerton, Caroline and MacDonald, Bryan and Arduini, Alessandro and Shi, Yunlong and Haas, Mary and Deik, Amy and Chaffin, Mark and Kovacs-Bogdan, Erika and Pacheco, Julian Avila and Amegadjie, Maiwen and Bhandary, Bidur and Sadre, Shayan and Rathjen, Thomas and Papangeli, Irinna and Chung, Raymond T and Goodman, Russell and Claussnitzer, Melina and Clish, Clary and Ehrmann, Alexander and Leed, Alison and Ellinor, Patrick T},
  title = {Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70507}
}
Kostenlos starten →